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Fourteen vendorsarecurrently sellingdepressioncaremanagementproducts toUS employersafterrandomizedtrialsdemonstrate
improved work outcomes. The research team interviewed 10 (71.4%) of these vendors to compare their products to four key
components of interventions demonstrated to improve work outcomes. Five of 10 depression products incorporate all four
key components, three of which are sold by health maintenance organizations (HMOs); however, HMOs did not deliver these
components at the recommended intensity and/or duration. Only one product delivered by a disease management company
delivered all four components of care at the recommended intensity and duration. This “voltage drop,” which we anticipate will




depressive episode each year [1]. Depression substantially
reduces an employee’s ability to work, as evidenced by
increased absenteeism [2–4] and reduced productivity at
work [2–7] with annual work costs approaching $24 billion
(Y2K $US) [1]. As the most prevalent disorder of the
principal conditions causing work loss in the American
workforce, [8, 9] depression will soon become the leading
cause of disability in industrialized countries [10].
Encouragingly, depression care management has been
shown to improve both clinical and work outcomes in
depressed employees. Depression care management provides
systematic education, monitoring, and clinician feedback
to individuals with depression. A randomized controlled
trial (RCT) conducted in depressed employees of over 100
companies demonstrated that depression care management
improved absenteeism and productivity at work over two
years, with no diﬀerential eﬀectiveness across the occupa-
tional spectrum [11]. A second RCT conducted in depressed
employees of 16 companies demonstrated that an inter-
vention providing depression care management improved
eﬀective work hours over one year [12]. The contribution
of depression care management to improved work outcomes
is further supported by Monte Carlo simulations and obser-
vational studies [13, 14]. Cost-beneﬁt analysis demonstrates
that depression care management intervention has the
potential to provide employers a return oninvestment across
a range of critical assumptions [15]. Scientists proceeded
to develop a calculator that employers can use to estimate
return on investment across critical assumptions [16]. The
calculator provides a conservative estimate of the impact of
depression care management on employer savings by using
salary/beneﬁts to assign an economic value to the impact,
although leading economic theorists note that this approach
consistently underestimates the losses employers absorb [17]
by assuming that economic gains are realized only when2 Depression Research and Treatment
work is not made up by coworkers and/or the employee and
by not including employer savings from reducing turnover.
Theoretically, employers can improve clinical outcomes
for their depressed employees while reducing their own costs
if (1) they purchase a product that provides the components
of evidence-based care at the intensity and duration shown
to improve clinical and work outcomes in eﬀectiveness trials
and, (2) these products are priced at levels that protect the
employers’ return on investment. The authors address the
ﬁrstconsiderationbycomparingtheproductsthatemployers
can currently purchase from vendors to key components
of the two RCTs demonstrating the ability of depression
caremanagement to improvework outcomesin “real-world”
populations and other scientiﬁc research. The objective here
is to compare the stated components of vendor products
to key components of models shown to improve work
outcomes.
2.Methods
The Colorado Business Group on Health (CBGH) identiﬁed
14 vendors who sold depression care management products
in 2009 by reviewing trade association membership lists,
by systematic inquiries to national health care organiza-
tions, and by web searches. The sample included 6 disease
management (DM) companies, 6 health plans (HP) four of
which were organized as HMOs, and 2 managed behavioral
healthcare (MB)organizations. Whenthe CBGHinterviewer
ﬁrst reached an employee at an eligible company (generally
a sales professional), the interviewer explained that a brief
survey on depression care management products was being
conducted, conﬁrmed that the company sold a depression
product meeting the study’s deﬁnition, and requested to
talk to a representative familiar with key components of the
depression product the company oﬀered (e.g., the eligible
respondent).The CBGHinterviewerexplained totheeligible
respondent that a survey was being conducted for the
Colorado Business Group on Health, a not-for-proﬁt health
coalition working with employers to increase value-based
purchasing. The interviewer explained that CBGH would
put information collected in this survey on the web to
educateemployersondepressioncare management products
that provided care in accordance with best practice. Eligible
respondents were not classiﬁed as nonrespondents until they
failed to respond to a minimum of 20 phone calls or emails.
In reviewing the research team’s proposal for this
manuscript, Florida State University’s IRB determined that
because subjects agreed to participate after being told that
identiﬁed product descriptions were to be published on the
web, the research project did not require human subjects
review. In this manuscript, the team takes an additional
step to protect respondents by removing all organizational
identiﬁers except vendor type.
The CBGH interviewer administered semistructured
questions (Table 1) about four key components of the
company’s depression product deﬁned from descriptions
of the two depression care management models shown to
improve clinical and work outcomes [11, 12]. Both models
provide screening, which has been identiﬁed as a critical
component of eﬀective depression care management models
in meta-analyses reviewing the international literature [18].
Both models provided protocolized education/monitoring
by health care professionals with mental health backgrounds
at comparable intensities; however, care management dif-
fered in duration, demonstrating improved work outcomes
only as long as the intervention lasted—24 months [11]
or 12 months [12]. In both models, care managers were
supervised by a mental health specialist or a primary care
physicianworking inconcertwithaconsultation-liaisonpsy-
chiatrist. In both models, care managers provided feedback
to treating primary care physicians (PCPs) when patients
failed to improve. These components closely overlap with
components of depression care management interventions
associated with improved clinical outcomes identiﬁed in
meta-analysis [18, 19], see (Table 2).
DM and MB respondents were also asked to note: (a)
which populations were eligible to receive depression care
management in the company’s last contract (employeesonly,
employees and spouses, children, retirees, and unemployed),
(b) which of up to three characteristics the vendor most
emphasizes in marketing its depression product (capacity to
improvework outcomes,capacitytoreducehealthcare costs,
depression product cost, purchaser satisfaction, or patient
satisfaction), and (c) descriptive data. HP respondents were
not asked (a) and (b) because health plans generally oﬀered
depression products to all enrolled members.
The research team completed the survey with 10 of 14
identiﬁed vendors (71.4%), with 4DM vendors refusing to
participate. Fourof the 6 health plans were HMOs delivering
health care to geographically concentrated populations, with
the remaining 2 health plans delivering capitated or fee
for service care to geographically dispersed populations.
All 10 vendors reported they had oﬀered depression care
management products for two or more years.
Product Components. Five of 10 depression products incor-
porated four key components of depression care manage-
ment shown to signiﬁcantly improve work outcomes: one of
2DM products, 0 of 2MB products, and 4 of 6HP products.
Among the 6HPs, 3HMOsand 1 otherHP oﬀereda product
that incorporated all four key components.
Systematic Screening. Depression products from all 10 ven-
dors provided systematic screening. The primary method of
screening used by products that provided depression care
management to geographically disperse areas was adminis-
trative database screening while the primary method used
by products serving geographically concentrated areas was
oﬃce-based screening.
Education and Monitoring. The depression products sold
by all 10 vendors provided protocolized education and
short-term monitoring. Both DM products provided long-
term monitoring, as did 4 of 6HP products. Among HP
products, 3 of the 4HMOs provided both short- and long-
term monitoring; however, monitoring was not provided byDepression Research and Treatment 3
Table 1: Survey questions.
Survey questions Criteria Addressed
(1) Does your depression care management product have a process to systematically identify
employees with depression? If yes, can you describe how you identify employees with depression?
If no, do you have the potential to do this if a purchaser requested it?
Criterion 1: engaging
eligible patients
(2) Does your depression care management product include systematically educating patients




(3) Does your depression care management program provide short-term monitoringof patients
(withinthe ﬁrst 6 months) to assess treatment adherence and symptom changes? If yes, how often
does the depression care manager contact the average program participant in the ﬁrst 6 months
after the patient is engaged in the program? Note “as needed” if that’s what the respondent says. If
no, do you have the potential to do this if a purchaser requested it?
Criterion 2b: short-term
monitoring
(4) Does your depression care management program provide long-term monitoring of patients
(beyond 6 months) to assess treatment adherence and relapse? If yes, how often does the
depression care manager contact the average program participant 7–24 monthsafter the patient is
engaged in the program? Note “as needed” if that’s what respondent says. If no, do you have the
p o t e n t i a lt od ot h i si fap u r c h a s e rr e q u e s t e di t ?
Criterion 2c: long-term
monitoring
(5) Does your depression care management product include regular care manager supervision by
a mental health professional? If yes, how often does the supervision occur on average? If no, do
you have the potential to do this if a purchaser requested it?
Criterion 3: care manager
supervision
(6) Does your depression care management program include contacting the patient’s primary
care or other referring physician if the patient fails to improve? If yes, how often does your
depression care manager contact the patient’s primary care physician in an average group of 100
program participants? (a) ∼1 in 100 program participants; (b) ∼10 in 100; (c) ∼20 in 100; (d)
more than 20 in 100. If no, do you have the potential to do this if a purchaser requested it?
Criterion 4: PCP contact
Table 2: Key components of DMW products.
Components Suggested intensity Suggested duration
Systematic identiﬁcation of eligible participantsa, b Once per patient Not applicable
Protocolized education/monitoringc by care manager
with mental health backgrounda, b
Planned contacts 0–6
monthsa and 7–24 monthsd 24 monthsd
Specialty supervision of care managersa, b Monthlya Ongoing
Care manager feedback to treating PCPse Care manager feedback to
Treating PCPse Ongoing
aUsed by both interventions [11, 12]s h o w nt oi m p r o v ew o r ko u t c o m e s .bSigniﬁcant in meta-analysis [19]. cNumber of contacts not signiﬁcant in meta-
analysis [19]. dUsed by one intervention [11]s h o w nt oi m p r o v ew o r ko u t c o m e s .eNot tested in meta-analysis. Although one of the two models oﬀered
telephonic psychotherapy as an option, it is not included as a key component because meta-analyses concluded this component did not improve clinical
outcomes [19].
any of the HMOs at the level of intensity shown to improve
work outcomes. Neither MB product provided long-term
monitoring.
Specialty Supervision of Care Managers. The depression
products sold by all 10 vendors provided specialty supervi-
sion of care managers.
Care Manager Feedback to Treating PCPs. One of 2DM
products and 1 of 2MB products provided care manager
feedback to treating PCPs. All HP products provided this
component of care.
Only DM and MB vendors provided information about
populations eligible to receive depression care management
in the company’s last contract. One DM and 1MB vendor
oﬀered the product to employees and spouses; 1MB vendor
oﬀered the product to employees only, and 1DM vendor
oﬀered the product to varied populations. DM and MB
vendors also provided data on characteristics the vendor
most emphasized in marketing its depression. All 4DM and
MB vendors emphasized their product’s capacity to improve
work outcomes, with 3 of the 4 vendors reporting that they
evaluated their product impact on this outcome. One DM
and 1MB vendor emphasized their product’s capacity to
reduce otherhealthcare costsand the productcost itself. Two
DM vendors emphasized customer satisfaction.
3.Discussionand Results
More than one-third of US healthcare spending is ﬁnanced
by employers who provide coverage to an estimated 90% of
nonelderly individuals with private health insurance [20].
Employers who are interested in purchasing a depression
product that improves work outcomes for the nearly 8%4 Depression Research and Treatment
of their workforce, face considerable challenges. Given that
the research community cannot agree on a deﬁnition of
collaborative care [21], it should not be surprising that
there is considerable variation in depression products on
the U.S. market. Five of 10 vendors sell a depression
product with the four key components identiﬁed in the
literature;3ofthese 5vendorswere HMOs.HoweverHMOs,
like other vendors, adopted product designs that delivered
education/monitoring at a lower intensity than shown to
improve work outcomes. Only one of 10 products (a DM
program) reported delivering the intensity and duration of
all four components shown to improve work outcomes over
two years [11].
Findings from the 4HMOs in this study may contribute
to eﬀorts of national health care delivery systems to provide
evidence-base care management for depression. Three of
4HMOs chose a model that incorporated all four com-
ponents of care; however, HMO leaders that championed
these programs indicated that it was a struggle to get
suﬃcient funding from their administrations to incorporate
all components at their recommended intensity and/or
duration. In response to budgetary constraints, program
leaders noted they had to prioritize program resources to
deliver care management to high risk cases only and/or
to reduce monitoring intensity. Given the impact of the
global recession on health care budgets around the world,
we suspect that national health care service eﬀorts to initiate
and sustain depression care management programs will face
similar pressures.
Many U.S. employers are unaware that their current
plans are not delivering high quality care to employees with
depression. U.S. employers who are aware are often stymied
because they purchase depression care as one part of a
complex package of services, which cannot easily be altered
to improve care for a given condition. Large employers,
who are expected to drive initial product demand [22, 23]
usually select products that provide centralized, rather than
oﬃce-based, care management. The advantage of centralized
models is that care managers can be trained to provide
protocolized education and monitoring. The challenge of
centralized modelsisthatpolicymakersperceiveitisdiﬃcult
to provide eﬀective feedback to PCPs located in other sites.
Encouragingly, half of centralized DM and MB products
provide feedback to treating PCPs. Questioned about the
eﬀectiveness of that feedback, the medical director for one
DM product noted that over 90% of PCPs were willing to
talk with him when he initiated a phone call; in remaining
cases, he reported good success in coaching patients to
request the necessary medication changes from their PCP.
The disadvantage of centralized products is that the admin-
istrative database screening that these models employcannot
identify more than half of depressed employees whose PCP
visits do not result in a depression diagnosis [24]. Because
PCPs consistently fail to recognize the problem when their
depressed patients present for care, depression screening
[25, 26] has repeatedly been shown to be an important (but
notstand-alone)componentofdepressioncaremanagement
programs [18].
We recognize the limitations of this study and its conclu-
sions. First, studying the stated components of a depression
care model produces a more encouraging picture than
studying the implementation of the model. We pursued this
line of inquiry when we recognized there were substantial
gaps between evidence-based care and the components of
care models that could only be expected to widen with
implementation. Second, a more ﬁne-grained approach
is needed to characterize important components of these
models such as education and monitoring. In a limited
survey, the research team prioritized studying monitoring
intensity over education because virtually all evidence-
based depression care management models specify repeated
monitoring during the acute and continuation phase of care.
In contrast, because repeated monitoring directly impacts
thecostofdepressioncaremanagement,vendorsdeliberately
reduce monitoring intensity. Third, we acknowledge that
even with concerted eﬀo r t s ,w ew e r ea b l et os u r v e y∼70% of
eligible respondents. All 4 respondents are disease manage-
ment ﬁrms, a pattern we suspect represents “nonignorable
missingness.” We were surprised when one DM company
whose clinical director expressed initial interest, refused to
participate after administrators reviewed the survey. Fourth,
there is a danger that ﬁndings from this article may be over-
interpreted as providing deﬁnitive criteria for high-quality
depression care management. We recognize that while the
evidenceforcollaborative care’s clinicaleﬀectivenessisbetter
established [18, 19] ,t h ee v i d e n c ef o ri t sc o s t - e ﬀectiveness
is less so [21, 27] .W h i l ea“ w h a tw ed o n ’ tk n o w ”p o s t u r e
protects the ﬁeld’s scientiﬁc credibility, it clearly fails to
translate “what we do know” to inform product selection
decisions that employers are currently making. Thus, we
a r g u et h a ti ti sr e a s o n a b l et oe v a l u a t et h ed e g r e et ow h i c h
depression products currently on the market incorporate
key components of interventions shown to improve work
outcomes, with the caveat that it will be necessary to
repeat this comparison on redeﬁned criteria, particularly
as additional research on cost-eﬀectiveness emerges. Fifth,
our study did not query vendors about cost and employee
participation,twocriticalingredientsforemployerstorealize
a potential return on investment in the purchase of these
products.TheCBGHcalculatorcitedaboveallowsemployers
to entercompany-speciﬁc information to estimate thereturn
on investment they can expect at given costs and employee
participation rates. When we piloted this study, we quickly
learned that vendors were unwilling to discuss product cost
with us perhaps because they did not want product prices
to be compared in public forums where it would be diﬃcult
to assure a favorable (or even fair) comparison. Future
investigators are encouraged to evaluate whether depression
products are priced at levels that protect the employers’
return on investment and the degree to which depressed
employees utilized these products once they are purchased,
as both these features are critical to employers trying to
purchase improved outcomes.
In characterizing how vendorstranslate health care inter-
ventions tested in intervention trials to sell to purchasers,
this paper documents one example of the considerable
challenges in translating scientiﬁc discovery to better healthDepression Research and Treatment 5
care. U.S. depression care management vendors have made
no cogent argument that the four components of evidence-
based care are impossible to integrate into a competitively
priced product that protects employer return on investment.
The fact that a centrally organized disease management
company sells such a product suggests that delivery systems
in the U.S. and abroad can integrate evidence-based care for
depression in current delivery systems.
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